Harvard Bioscience Q1 revenue $20.8M, gross margin 59%; reaffirms FY guidance

HARVARD BIOSCIENCE INC

2026-Q1 EPS reported -$0.77 vs consensus -$0.63 ▼ miss (-21.8%)

Revenue $20.8M (down 5% YoY from $21.8M); net loss $(3.4)M vs $(50.3)M including $48M impairment.
Gross margin 59% (vs 56% prior year); driven by higher-margin NPI mix (MeshMEA, BTX, SoHo).
Adjusted EBITDA $0.8M flat YoY; cash used in ops $(0.7)M vs $3.0M in Q1 2025.
Reaffirms full-year 2026 guidance; manufacturing consolidation on track for efficiencies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HARVARD BIOSCIENCE INC reported the first quarter ended March 31, 2026 results: revenue $20.8 million, net income $(3.4) million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $20.8 million
Net income: $(3.4) million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

margin NPI sales growth driving bottom line growth in the second half of the year.” First Quarter 2026 Results For the first quarter of 2026, the Company reported revenues of $20.8 million compared to $21.8 million in the first quarter of 2025. Gross margin for the first quarter of 2026 was 59%, compared to 56% in the first quarter of 2025. Net loss for the first

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-26-003270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.